Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 6/20 | 0.41 |
| ▸ | HTR2B | P41595 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17661774 | 0.85 | KDR (0.41) | HTR2CHTR2BHTR2AKDRPDGFRB | |
| Hydrochloric Acid SCHEMBL17645608 | 0.84 | KDR (0.40) | HTR2CHTR2BHTR2AKDRPDGFRB | |
| SCHEMBL3222463 | 0.73 | HTR6 (0.41) | HTR6HTR2CPOLBSMN1; SMN2ASIC3 | |
| SCHEMBL25273694 | 0.72 | KDR (0.41) | HTR2CHTR2BHTR2AKDRPDGFRB | |
| SCHEMBL17645631 | 0.72 | HTR6 (0.40) | HTR6HTR2CPOLBSMN1; SMN2PNMT | |
| SCHEMBL6208201 | 0.70 | KDR (0.39) | HTR2CHTR2BHTR2AKDRPDGFRB | |
| SCHEMBL31391902 | 0.70 | KDR (0.36) | HTR2CHTR2BHTR2AKDRPDGFRB | |
| SCHEMBL16220603 | 0.67 | PNMT (0.38) | HTR6POLBSMN1; SMN2ASIC3PNMT | |
| SCHEMBL10095074 | 0.67 | POLB (0.47) | HTR6HTR2CPOLBSMN1; SMN2ASIC3 | |
| SCHEMBL15088358 | 0.66 | BPTF (0.39) | HTR6HTR2CPNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388181-B2 | Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388181-B2 | Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388181-B2 | Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | TK1, CDK2, MAP4K2 | HTR6 1589/4885HTR2C 1267/4885HTR2B 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.